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Abstract
Background The precise role of total body 18F-  uorodeoxyglucose-positron emission tomography/computed tomog-
raphy (PET/CT) in the clinical management of patients with cutaneous malignant melanoma (CMM) is not well estab-
lished.
Objective The purpose of this study was to investigate the diagnostic accuracy of PET/CT in early- and late-stage
patients with high-risk CMM.
Methods We retrospectively analysed various imaging, histopathological and clinical data from 97 patients also exam-
ined by PET/CT during a 5-year period (2007 2011). Three groups were assessed: stage I/II, resected stage III and unre-
sectable stage III/stage IV.
Results The median follow-up time of living patients was 43.48  19.67 (15 142) months. We observed a high diag-
nostic accuracy in all stages (91.3%, 92.5% and 96.2% respectively). PET/CT appeared to be reliable diagnostic tool
even for the detection of small lymph node metastases. PET/CT was informative in 14 of 19 cases wherein another imag-
ing examination provided inconclusive results regarding lesion dignity. However, PET/CT was less suitable for properly
evaluating the dignity of a lung lesion. A true positive scan was twice as likely in clinically negative patients with resected
stage III disease than in patients with stage I/II disease (35.9% and 14.5%, P = 0.007).
Conclusions These results con rm that PET/CT is an important diagnostic tool in the management of patients with
high-risk CMM, but it cannot replace the standard of care examinations. More accurate clinicopathological and timing
1
criteria must be de  ned to best utilize the advantages of this imaging method.
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Introduction
The incidence of cutaneous malignant melanoma (CMM) in
fair-skinned populations is increasing worldwide.1,2 The distant
metastasis rate, which determines melanoma-associated mortal-
ity, is increased in cases with high Breslow tumour thickness,
ulceration, a high mitotic rate of primary CMM and positive
nodal status. These factors are considered in the current TNM
staging system according to American Joint Committee on Can-
cer.3 Currently, despite the use of adjuvant treatment in patients
with an increased metastasis risk, disease recurrence can occur at
any time or site. Early identiÞcation of metastasis and an assess-
ment of the aggressiveness of the spread of the disease are rele-
vant pieces of information for optimized therapeutic decisions
for choices between currently available metastatic CMM treat-
ment approaches. Thus, appropriate radiological and nuclear
medicine imaging methods are of great importance. The advan-
tages of 18F-ßuorodeoxyglucose (FDG)-positron emission
tomography (PET)/computed tomography (CT; hereafter
referred to as PET/CT) include the ability to simultaneously pro-
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activity of a suspicious lesion, as well as real-time whole-body
imaging. The disadvantages of PET/CT include the high cost
and the reduced sensitivity of detection of metastases in organs
with high glucose uptake, such as the brain. Several studies have
demonstrated the beneÞt of PET/CT in CMM, but questions
concerning the adequate indication for this imaging tool remain.
The diagnostic role of PET/CT has not been substantially evalu-
ated in early CMM stages (AJCC stages I and II).4 However, con-
sidering the high rate of PET/CT false-positive Þndings and the
cost of whole-body imaging examinations compared with the
low rate of nodal disease (less than 15%) and distant metastasis
(less than 5%) at the time of primary diagnosis,5 the standard
method for initial staging (for which PET/CT is not a suitable
option) remains the sentinel lymph node biopsy (SLNB).6 Nev-
ertheless, among high-risk melanoma patients with stage I/II dis-
ease, a high diagnostic accuracy for PET/CT in the detection of
metastases has been reported in two different studies (91% and
98%).7,8 The use of PET/CT to examine staging in patients with
stage III disease is more accepted. The aim of this study was to
assess the diagnostic accuracy of PET/CT in CMM at various
(early and late) disease stages in a retrospective cohort study.
Materials and methods
Demography and PET/CT examinations
Whole-body 18F-FDG-PET/CT imaging was performed in 121
consecutive patients with CMM who were referred from the
Department of Dermatology of University of Debrecen Medical
Centre between January 2007 and December 2011. After the
exclusion of cases without eligible follow-up data and a histo-
pathologically unveriÞed diagnosis of the primary CMM excised
on an unknown date, 97 patients were evaluated (Table 1). Of
the 97 patients, 40 (41.2%) had two, three or four PET/CT scans.
Therefore, 148 PET/CT scans could be analysed with corre-
sponding clinical and histopathological data (Tables 2 4).
Patients who were still alive received follow-up for at least
12 months after PET/CT. Of the 148 PET/CT scans, 69 (46.6%)
were performed in patients with stage I and stage II tumours
(group 1), 53 (35.8%) in patients with resected stage III tumours
(group 2) and 26 (17.6%) in patients with unresectable stage III
and resected or unresectable stage IV tumours (group 3). The
diagnostic accuracy of PET/CT was assessed separately in the
three groups. Clinical follow-up data were reviewed carefully
with regard to the inßuence of the PET/CT result on the clinical
management, the recurrence of disease after a true negative PET/
CT, and the utility of a PET/CT result after another imaging
examination provided inconclusive results regarding lesion
dignity.
18F-FDG-PET/CT imaging procedure
The PET/CT examinations were performed at the ScanoMed
Debrecen Centre according to their melanoma PET/CT protocol
using a Philips Gemini TF 64 PET/CT scanner. Total body
images were obtained from the top of the head to the toes.
Patients fasted for at least 6 h prior to the examination. Glucose
le ls were measured prior to the FDG injection to ensure that
the value was not greater than 12 mmol/L.18F-FDG [4.4 MBq
(0.12 mCi)/kg] was intravenously administered to each patient
1 h before PET image acquisition. During this uptake time, each
patient consumed 1000 mL water. Low-dose CT (120 KV and
100 200 mAS depending on the patientÕs bodyweight) was per-
formed over the entire range for attenuation correction and ana-
tomical localisation. PET acquisition was subsequently
performed over the entire range (50% overlap, 18 cm axial Þeld
of view, 3D time of ßight technique). The acquisition times were
60 150 s/frame from the top of the head to the upper thigh
based on the patientÕs bodyweight and 60 s/frame from the
upper thigh to the toes in each case. Images were reconstructed
using the 3D-RAMLA iterative technique. Images were inter-
preted by experienced nuclear medicine and radiology specialists
working at the ScanoMed Centre who were familiar with previ-
ous PET/CT results (if available).
Assessment of diagnostic accuracy
Interpretation of PET/CT was accepted as true positive or true
negative if the presence or absence of metastases revealed by the
examination were consistent with histopathological and/or clini-
cal data during the follow-up. The diagnosis was deÞned as false
positive in the following cases: when the histopathological exam-
ination of the indicated lesion was negative or when a suspicious
lesion became undetectable by other imaging modalities during
the minimum 12-month clinical follow-up. PET/CT results were
evaluated as false negative in cases of histopathologically veriÞed
disease recurrence within 3 months of a negative scan. By deÞni-
tion, the diagnostic accuracy is calculated from the following
equation: (number of true positive cases+ number of true nega-
tive cases) / (number of true positive cases+ number of true
negative cases+ number of false negative cases+ number of
false positive cases).
Statistical analysis
The data were statistically analysed using the independentt-t s ,
Mann Whitney U-test, and the Pearson Chi-squared test (SPSS
for Windows, version 19.0, SPSS Inc., Chicago, IL, USA). Test
results were deÞned as signiÞcant ifP < 0.05.
Results
Clinical beneﬁts of PET/CT examinations
The demographic and clinicopathological data from patients
undergoing PET/CT examination during a 5-year period (2007
2011) are summarized in Table 1. Based on their clinicopatho-
logical parameters (Breslow tumour thickness, ulceration and
lymph node status), these patients were at high risk of disease
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recurrence. The proportions presented are not consistent with
the characteristics of the entire population with CMM cared for
in the department (these data are beyond the scope of this
study). In 97 patients, 148 PET/CT scans were performed
(Table 2), primarily for (re-)staging (Table 3). After PET/CT
examination, the mean follow-up time of patients alive was
43.48  19.67 months. The rate of the change in stage due to
the PET/CT result was increased in resected stage III patients (14
of 53) compared with stage I/II patients (eight of 69). PET/CT
was informative in 14 of 19 cases wherein another imaging
examination provided inconclusive results regarding lesion dig-
nity (equivocal lymph node enlargement; lung and subcutaneous
nodule). Metastasis was confirmed in six of 14 cases and
excluded in eight of 14 cases. Reviewing the clinical follow-up
data, we found that the PET/CT result influenced the clinical
management of 28.4% of patients. The surgical removal of
lymph node, subcutaneous, lung, brain and mesenteric metasta-
sis was noted in 10.8% of patients. In addition, 21.6% of patients
were administered systemic treatment, and surgical excision and
systemic therapy was provided to 8.8% of patients. Of note, we
observed disease recurrence in 22.6% of patients with stage I/II
tumours within 4–15 months after a true negative PET/CT. This
rate was slightly lower (16.7% within 4–12 months) in resected
stage III tumours. The sites of recurrences included regional
lymph nodes (8/12 in stage I/II and 3/5 in resected stage III
respectively) or distant organs (4/12 in stage I/II and 2/5 in
resected stage III respectively).
PET/CT exhibits a high diagnostic accuracy
Group 1: patients with resected stage I and stage II disease Of
the 69 PET/CT scans, 54 were negative, 53 (76.8%) were true neg-
ative and one was false negative (Table 4). In the latter case, a his-
topathologically confirmed subcutaneous recurrence of CMM at
the primary site was removed within 3 months of the examina-
tion. Of the 69 PET/CT examinations, ten (14.5%) were true
positive, and five were false positive. Most of the true positive
PET/CT examinations were performed in the first year, and
Table 1 Patient demographics
Patients
Male Female Total
N (%) 47 (48.5) 50 (51.5) 97 (100)
Age, mean  SD, min–max (years) 52.55  12.80, 28–81 50.72  13.23, 23–77 51.61  12.99, 23–81
Clinicopathological type N (%)
Superﬁcial spreading melanoma 21 (44.7) 23 (46.0) 44 (45.4)
Nodular melanoma 21 (44.7) 22 (44.0) 43 (44.3)
Not classiﬁed 4 (8.4) 4 (8.0) 8 (8.2)
Occult 1 (2.1) 1 (2.0) 2 (2.1)
Ulceration, N (%) 18 (38.3) 18 (36.0) 36 (37.1)
Breslow, mean  SD, median (mm) 4.57  6.54, 2.28 4.07  3.57, 2.86 4.32  5.23, 2.70
Breslow (mm) N (%)
≤1.00 9 (19.1) 6 (12.0) 15 (15.5)
1.01–2.00 10 (21.3) 13 (26.0) 23 (23.7)
2.01–4.00 11 (23.4) 10 (20.0) 21 (21.6)
≥4.01 15 (31.9) 17 (34.0) 32 (33.0)
Occult 1 (2.1) 1 (2.0) 2 (2.1)
Unknown 1 (2.1) 3 (6.0) 4 (4.1)
Localisation N (%)
Trunk 25 (53.2) 21 (42.0) 46 (47.4)
Lower extremities 9 (19.1) 12 (24.0) 21 (21.6)
Upper extremities 7 (14.9) 5 (10.0) 12 (12.4)
Head-neck 5 (10.6) 11 (22.0) 16 (16.5)
Occult 1 (2.1) 1 (2.0) 2 (2.1)
AJCC stage at diagnosis N (%)
IA–IB 17 (36.2) 13 (26.0) 30 (30.9)
IIA–IIC 22 (46.8) 25 (50.0) 47 (48.5)
IIIA–IIIC 8 (17.0) 11 (22.0) 19 (19.6)
IV 0 (0.0) 1 (2.0) 1 (1.0)
Follow-up time of living patients, mean  SD, min–max (months) 42.34  18.97, 15–96 42.25  20.26, 18–142 43.48  19.67, 15–142
























































metastatic lymph nodes (8 20 mm in diameter) were detected in
half of the scans. This Þnding indicates that these cases would
have been SLN-positive melanomas, but SLNB was not performed
initially due to head/neck localization, multidirectional lymphatic
drainage detected by lymphoscintigraphy, or patient-related
reasons. It should be mentioned that despite the early detection of
metastases by PET/CT and subsequent therapeutic interventions,
the rate of rapid disease progression was increased in this patient
group (70%). One of the false-positive cases involved an enlarged
distant lymph node in the left parailiacal region with increased
Table 2 PET/CT examinations
Patients
Male Female Total
Number of PET/CT, N (%) 65 (43.9) 83 (56.1) 148 (100)
Number of PET-CT per patient N (%)
1 34 (72.3) 23 (46.0) 57 (58.8)
2 9 (19.2) 21 (42.0) 30 (30.9)
3 3 (6.4) 6 (12.0) 9 (9.3)
4 1 (2.1) 0 (0.0) 1 (1.0)
AJCC stage at PET-CT N (%)
I/II 27 (41.5) 42 (50.6) 69 (46.6)
resected III 23 (35.4) 30 (36.1) 53 (35.8)
unresectable III/IV 15 (23.1) 11 (13.3) 26 (17.6)
AJCC stage at PET-CT Relapse after a true negative PET/CT*, N (%)
I/II 5 (62.5) 7 (63.6) 12 (22.6)
resected III 2 (25) 3 (27.3) 5 (16.7)
unresectable III/IV 1 (12.5) 1 (9.1) 2 (50.0)
*Disease recurrence was detected>3 months after the PET/CT scan.
Table 3 PET/CT indications and the rate of the change in stage
Indication N (%) PET/CT result
(Re-)staging 129 (87.2) 99 unchanged status
18 change in stage
9 progression
3 complete remission
Results of other imaging examinations were uncertain 19 (12.8) 6 veri  ed recurrence/progression
8 progression excluded
5 remained uncertain
AJCC stage at the change in stage
I/II 8 (11.6) 4 regional lymph node metastasis
4 distant lymph node, lung, or bone metastases
resected III 14 (26.4) 5 distant lymph node, or subcutaneous metastases
9 lung, bone, brain, or liver metastases







Total Sensitivity Speciﬁcity Diagnostic
accuracy
PPV NPV
N 50 87 10 1 148 98.0 89.7 92.6 83.3 98.9
AJCC stage at PET/CT N (%)
I/II 10 (14.5) 53 (76.8) 5 (7.3) 1 (1.4) 69 (46.6) 90.9 91.4 91.3 66.6 98.1
resected III 19 (35.9) 30 (56.6) 4 (7.5) 0 (0) 53 (35.8) 100 88.2 92.5 82.6 100
unresectable III/IV 21 (80.7) 4 (15.4) 1 (3.8) 0 (0) 26 (17.6) 100 80.0 96.2 95.45 100
PPV, positive predictive value; NPV, negative predictive value.
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FDG uptake, which was surgically removed; the histopathological
examination indicated reactive lymphadenopathy. Another case
involved a solitary regional lymph node in the right axillary
region that was not detected by subsequent follow-up ultrasound
(US) examinations. There were five uncertain results, which were
counted as positive scans. In three of the five uncertain cases,
non-calcified nodules with uncertain dignity were visualized in
the lungs by PET/CT. During the clinical follow-up, thorax CT
indicated nodule disappearance in two cases (false positive),
whereas pulmonary metastases were observed in the third case
(true positive). In the fourth case, the mediastinal lymph nodes
were interpreted as uncertain positive lesions that were not
detected either by thorax CT 3 months later or by PET/CT 1 year
later (false positive). In the fifth case, an axillary regional lymph
node was described with uncertain dignity, and both the fine nee-
dle aspiration biopsy (FNAB) and the histopathological examina-
tion of block-dissection confirmed lymph node metastasis (true
positive). Overall, the sensitivity of PET/CT in stage I/II tumours
was 90.9%, the specificity was 91.4% and the diagnostic accuracy
was 91.3%.
Group 2: patients with resected stage III disease Of the 53
PET/CT examinations, 30 (56.6%) were true negative, and 19
(35.9%) were true positive. No false-negative results were
obtained. Of these 53 PET/CT scans, four (7.5%) were false posi-
tive. A regional lymph node in one case and a distant lymph node
in another case, both with increased FDG uptake, were identified
as metastatic lesions. However, FNAB was negative in both cases,
and the lymph nodes subsequently became undetectable in fol-
low-up US examinations. In the third case, a subcutaneous nod-
ule was detected in an in-transit location but was undetectable in
the next follow-up US examination as well as by a subsequent
PET/CT scan 6 months later. The fourth false-positive case
involved a pelvic mass with increased FDG uptake that was unde-
tectable by US either at that time or during subsequent follow-up.
Only one case was noted wherein a subcutaneous mass with mod-
erate FDG uptake in the left inguinal region was depicted as a
lesion with uncertain dignity. We decided to remove this lesion
because it was close to the surgical scar of the previous block dis-
section. Histopathological examination revealed that the lesion
was a subcutaneous in-transit metastasis. Overall, in resected stage
III tumours, the sensitivity of PET/CT was 100%, the specificity
was 88.2% and the diagnostic accuracy was 92.5%.
Group 3: patients with unresectable stage III and resected or
unresectable stage IV disease Of the 26 examinations, 21
(80.7%) were true positive, and four (15.4%) were true negative.
The indication for PET/CT at this stage primarily involved the
assessment of therapeutic efficacy. One false-positive case proved
to be a submandibular lymph node. In one case, FDG-positive
nodules were detected in the apex of both lungs by PET/CT. Based
on the localization of the nodules and the distribution of FDG
uptake, the scan was interpreted to be uncertain with the possibil-
ity of reactivation of pulmonary tuberculosis. Neither thorax CT
nor bronchoscopy with cytological examination and mycobacte-
rial culturing led to a diagnosis. We considered the case to be a
lung metastasis; however, lymph node and in-transit metastases
progressed without deterioration of the pulmonary status. Overall,
in this advanced stage, the sensitivity of PET/CT was 100%, the
specificity was 80% and the diagnostic accuracy was 96.2%.
Discussion
The early detection and appropriate treatment of lymph node or
distant metastases are important factors in the overall survival of
CMM patients. The diagnostic sensitivity of FDG-PET in this
disease is 90% for metastatic nodules ≥78 mm3 in volume
(approximately ≥5.3 mm in diameter).9,10 Thus, FDG-PET is
unable to detect micrometastases in patients with clinically local-
ized CMM; therefore, it was concluded that FDG-PET scanning
is not of use in the initial staging of these patients.11 FDG-PET
combined with CT increased the diagnostic accuracy,12 and sev-
eral studies have demonstrated that PET/CT is superior to PET
or CT alone as well as other conventional imaging methods.13–15
Several studies have been conducted to determine the role of
PET/CT in primary staging and restaging in early-stage and
high-risk melanoma patients.10,16–29 From these, the reported
ranges for diagnostic sensitivity were 0 to 100% in AJCC stages I
and II and 68 to 87% in AJCC stages III and IV.18
Our study demonstrates the high diagnostic accuracy (92.6%)
of PET/CT. The reduced accuracy observed in cases of lymph
node, pulmonary and subcutaneous metastases is consistent with
previous reports.7 For example, pulmonary nodules smaller than
12 mm in diameter may be FDG negative despite their meta-
static origin, and additional examinations, such as a follow-up
CT of the thorax 3 months later, are required.7,30 PET/CT also
exhibits a disadvantage in the detection of central nervous sys-
tem metastases. The accuracy of PET/CT to detect metastases in
the central nervous system is also reduced given the increased
glucose uptake of grey matter and variations in the pattern of
the FDG uptake of melanoma brain metastases (hypermetabolic,
hypometabolic or ring like).31,32 There is no doubt that MRI is
the most appropriate imaging technique to investigate the cen-
tral nervous system and to exclude its involvement in metastatic
disease. Nevertheless, given the high prevalence of brain metasta-
sis in metastatic melanoma and the likelihood of detecting a
brain metastasis by PET/CT even in an asymptomatic patient, as
observed in three of 97 patients in this study, PET/CT imaging
must include the investigation of head in melanoma patients.32
By comparing the diagnostic accuracy of PET/CT in various
disease stages, we observed reduced specificity in resected stage
III tumours compared with stage I/II tumours, where the
technique exhibits reduced sensitivity. However, the diagnostic
accuracy was high in both stages (91.3% and 92.5% respec-
tively).
























































As expected, most of the true positive PET/CT scans were
obtained from advanced stage patients, and most of the true
negative PET/CT examinations were obtained from stage I/II
patients. In this study population, a true positive scan was twice
as likely in patients with resected stage III disease than in
patients with stage I and stage II disease (P = 0.007). No signiÞ-
cant difference was noted between the clinicopathological fea-
tures of patients with true negative and true positive PET/CT
scans (data not shown). In terms of prognosis, based on clinical
follow-up data, the rate of disease progression was increased
after a true positive PET/CT in all stages (70.0%, 73.7% and
81%) despite treatment. Nevertheless, a relatively high rate of
disease recurrence (22.6%) was obvious in stage I/II patients
soon (within 4 15 months) after a true negative PET/CT. This
rate was slightly lower (16.7% within 4 12 months) in resected
stage III tumours. If we consider a PET/CT scan to be a false
negative when the disease recurs at any time during the observa-
tion period after a negative PET/CT, the diagnostic accuracy of
PET/CT is reduced. However, the accuracy remains high, with
rates of 91.3% in stage I/II, 92.5% in resected stage III and
96.2% in unresectable stage III/stage IV tumours.
The high diagnostic accuracy of PET/CT makes this imaging
technique an appropriate tool for use in CMM staging; however,
the optimum timing of the PET/CT scan to ensure cost-related
and patient-related beneÞts remains unclear. PET/CT does not
appear to be useful for initial staging or during regular follow-
up of low-risk CMM patients (stage I), who comprise the major-
ity of melanoma cases.5 In the initial staging of high-risk patients
with stage IB/II tumours, the SLND must be the Þrst choice.
Our results justify the utility of PET/CT in the (re)staging of
CMM patients with diagnosed stage III but suggest that PET/CT
may also be beneÞcial for stage I/II patients in a selected high-
risk population where SLND is negative or could not be per-
formed. Which of the clinicopathological and/or immunohisto-
chemical parameters of the primary tumour can be used for
selection requires clariÞcation.33 Most of the PET/CT-positive
cases in stage I/II were associated with the aggressive clinical
behaviour of CMM; however, in general, only lymph nodes were
initially detected by PET/CT.
In conclusion, PET/CT is an important diagnostic method in
the management of patients with high-risk CMM; however, the
technique cannot replace close clinical follow-up. Optimized
stage-related patient selection and the optimum timing of the
PET/CT scan must be established by further studies to best uti-
lize the advantages of this imaging method. This study provides
additional information.
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